Here are the DEF 14A proxy statements from NeoGenomics, Inc. (NEO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow NEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEO filings page.
NeoGenomics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 21, 2026. Proposals include electing nine directors, approving executive pay on an advisory basis, expanding the 2023 Equity Incentive Plan, and ratifying Deloitte & Touche LLP as auditor for 2026.
The equity plan amendment would increase shares reserved for issuance by 5,000,000 shares to a total of 13,300,000 shares, supporting future stock options and RSUs. As of March 23, 2026, 1,961,604 shares remained available and 13,934,021 options and stock awards were outstanding. The proxy also highlights strong board independence, share ownership guidelines, and extensive stockholder outreach on compensation and governance.